DIPSS Plus Score: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Tag: New redirect
 
Tag: Removed redirect
Line 1: Line 1:
#REDIRECT: [[Myelofibrosis natural history, complications and prognosis#DIPSS Plus Score for Prognosis in Myelofibrosis]]
__NOTOC__
{{CMG}}; {{AE}} {{SSH}}
==Overview==
Dynamic International Prognostic Scoring System (DIPSS)‐plus scoring system comprises of eight risk variables to predict the prognosis in myelofibrosis.
==DIPSS Plus Score Calculator==
=== DIPSS plus score for prognosis in myelofibrosis ===
*This handy calculator computes the prognosis in myelofibrosis using Dynamic International Prognostic Scoring System (DIPSS)‐plus. This scoring system comprises of eight risk variables.<ref name="pmid21149668">{{cite journal |vauthors=Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A |title=DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status |journal=J. Clin. Oncol. |volume=29 |issue=4 |pages=392–7 |date=February 2011 |pmid=21149668 |doi=10.1200/JCO.2010.32.2446 |url=}}</ref><ref name="pmid27870387" /><ref name="pmid27521306">{{cite journal |vauthors=Bose P, Verstovsek S |title=Prognosis of Primary Myelofibrosis in the Genomic Era |journal=Clin Lymphoma Myeloma Leuk |volume=16 Suppl |issue= |pages=S105–13 |date=August 2016 |pmid=27521306 |pmc=4987499 |doi=10.1016/j.clml.2016.02.031 |url=}}</ref>
Check all boxes that apply to your patient:
 
{{#Widget:DIPSS_Plus_Score}}
 
=== Interpretation of DIPSS plus score ===
* Score = 0: Low risk group; estimated median survival is approximately 15.4 years
* Score = 1: Intermediate-1 risk group; estimated median survival is approximately 6.5 years
* Score = 2 or 3: Intermediate-2 risk group; estimated median survival is approximately 2.9 years
* Score ≥ 4: High risk group; estimated median survival is approximately 1.3 years
 
==References==
{{Reflist|2}}
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Oncology]]
[[Category:Neurology]]
[[Category:Neurosurgery]]
[[Category:Up-To-Date]]
[[Category:Primary care]]
[[Category:Calculator]]

Revision as of 03:33, 26 January 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Dynamic International Prognostic Scoring System (DIPSS)‐plus scoring system comprises of eight risk variables to predict the prognosis in myelofibrosis.

DIPSS Plus Score Calculator

DIPSS plus score for prognosis in myelofibrosis

  • This handy calculator computes the prognosis in myelofibrosis using Dynamic International Prognostic Scoring System (DIPSS)‐plus. This scoring system comprises of eight risk variables.[1][2][3]

Check all boxes that apply to your patient:

DIPSS Plus Score for Prognosis in Myelofibrosis
Variable Score
Age >65 years 1
Constitutional symptoms 1
Hemoglobin <10 g/dL 1
Leucocyte count >25 x 10⁹/L 1
Circulating blasts ≥1% 1
Unfavourable karyotype (complex karyotype or abnormalities that include +8, -7/7q-, i(17q), inv(3), 5/5q-, 12p-, or 11q23 rearrangement) 1
Transfusion dependency 1
Platelet count <100 x 10⁹/L 1
DIPSS Plus Score:
Interpretation:

Interpretation of DIPSS plus score

  • Score = 0: Low risk group; estimated median survival is approximately 15.4 years
  • Score = 1: Intermediate-1 risk group; estimated median survival is approximately 6.5 years
  • Score = 2 or 3: Intermediate-2 risk group; estimated median survival is approximately 2.9 years
  • Score ≥ 4: High risk group; estimated median survival is approximately 1.3 years

References

  1. ↑ Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (February 2011). "DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status". J. Clin. Oncol. 29 (4): 392–7. doi:10.1200/JCO.2010.32.2446. PMID 21149668.
  2. ↑
  3. ↑ Bose P, Verstovsek S (August 2016). "Prognosis of Primary Myelofibrosis in the Genomic Era". Clin Lymphoma Myeloma Leuk. 16 Suppl: S105–13. doi:10.1016/j.clml.2016.02.031. PMC 4987499. PMID 27521306.
Retrieved from "https://www.wikidoc.org/index.php?title=DIPSS_Plus_Score&oldid=1541453"